Kornimate/medical-research-clean huggingface dataset:
does application time influence the effect of massage on pain and performance?

Conditions: Health, Subjective

Summary: introduction: the massage technique is widely used for post-exercise recovery, however, there is still a gap regarding the ideal dosage in relation to the duration of its application. objective: to analyze the influence of massage when applied at different times on the dominant (dom) and non dominant (ñdom) quadriceps muscles and clinical variables. methods: study carried out with 11 men aged 21.5(2.1) years, in a two-week crossover design. participants performed a jumping protocol followed by manual massage for 5 (g1) or 10 (g2) minutes. assessments included strength testing, pain scale (vas), perception of recovery and vital sign measurements up to one hour post-massage. analysis onducted in spss, anova was performed (with bonferroni test, when necessary), providing effect sizes (p\<0.05).

the massage technique is widely used for post-exercise recovery, however, there is still a gap regarding the ideal dosage in relation to the duration of its application. the objective was to analyze the influence of massage when applied at different times with the participation of 11 men, in a two-week crossover design. participants performed a jumping protocol followed by manual massage for 5 (g1) or 10 (g2) minutes. assessments included strength testing, pain scale (vas), perception of recovery and vital sign measurements up to one hour post-massage.

Eligibility criteria:
iinclusion criteria: * students * mens * aged 18 to 35 years * healthy (self-report) regularly enrolled in the physiotherapy course at the northern paraná state university (uenp), from the 1st to the 5th year * who have not undergone * surgery in the last spine and lower limbs and were instructed not to perform any physical activity in the last 24 hours before the test. exclusion criteria: * people who are not enrolled in the physiotherapy course at the state university of northern paraná * are not in good health * have undergone surgery on the lower limbs within a period of 12 months * have practiced physical activity in the last 24 hours

Keywords: massage recovery of function muscle strength
pilot trial of a behavioral treatment for epilepsy

Conditions: Epilepsies, Partial

Summary: the purpose of this research study is to see if a behavioral program which includes a relaxation technique and lifestyle changes can improve seizure control and well-being in epilepsy patients.

the behavioral treatment approach studied aims to help epilepsy patients discover which circumstances and behaviors trigger their seizures. the most common seizure precipitants are irregularities of sleep, sensory triggers such as flashing lights and emotional stress. patients will learn how to avoid seizure precipitants and how to stop seizures in their first beginnings. study participants will continue their prior medications.

Eligibility criteria:
inclusion criteria: * age 16-50 years. * reliable diagnosis of partial epilepsy, including simple or complex partial or secondarily generalized tonic-clonic seizures. * average seizure frequency of at least one partial seizure per month for at least one year. * willing not to begin another new treatment other than anticonvulsants (acupuncture, botanicals or other mind-body interventions, ketogenic diet, vagus nerve stimulator, or epilepsy surgery) while enrolled in the study. exclusion criteria: * unreliable history of seizure semiology. * average seizure frequency less than one seizure per month. * patients in whom it is anticipated that current standard of care would mandate a change in their conventional epilepsy treatment during the time period of the study will be excluded. * patients taking more than 2 anticonvulsant medications will be excluded. * patients with serious other medical problems, such as brain tumors, cancer, stroke, significant heart disease or psychiatric disorders will be excluded. * patients with a high likelihood of psychogenic or nonepileptic seizures will be excluded. * patients with progressive epilepsy syndromes, neurodegenerative disorders or significant mental retardation will be excluded.

Keywords: behavior therapy relaxation techniques
feasibility trial of a one-day cbt workshop ("discover") for 15-18 year olds with anxiety and/or depression in clinics

Conditions: Anxiety; Depression

Summary: this is a feasibility trial designed to test the feasibility and acceptability of a one-day cognitive behavioural therapy (cbt) workshop intervention ("discover") for young people aged between 15-18 years, who are on local child and adolescent mental health services (camhs) waiting lists, awaiting treatment for difficulties with anxiety and/or depression. participants will be randomised to receive either the discover workshop (in addition usual care) or to continue usual care.

sclare and colleagues (2015) have developed an open-access intervention ("discover") for 16-18 year olds experiencing emotional problems, in the form of one-day cbt-based workshops, delivered in schools. discover has been tested in schools and preliminary outcomes have shown to be positive. given the lengthy waiting lists of some camhs services, the present study seeks to explore whether the discover programme can be implemented in clinic settings, with a broader age range of 15-18 year olds, with the aim of providing young people with some form of help, whilst they are awaiting more individualised treatment. fifteen to eighteen year olds awaiting treatment for anxiety and/or depression will be recruited from local camhs waiting lists, and randomised to receive either the discover workshop, delivered in clinic (in addition to usual care), or to continue usual care. the study will assess the feasibility, acceptability and range of outcomes of discover in clinic settings.

Eligibility criteria:
inclusion criteria: 1. aged 15-18 years; 2. fluent in english; 3. currently on a local camhs waiting list for treatment based on a referral for emotional difficulties (anxiety and/or depression); 4. willing and able to attend a one-day workshop within clinic; and 5. their position on the waiting list must indicate that they are unlikely to receive a camhs treatment appointment in the 8 weeks following the workshop. exclusion criteria: 1. presenting with acute risk of harm to self or others; 2. have severe learning difficulties; and 3. are unable to provide informed written consent to participate and are unable to complete assessments.
gastric cancer liver metastasis cohort of china

Conditions: Stomach Neoplasms; Neoplasm Metastasis

Summary: this multi-institutional retrospective cohort study aimed to describe and analyze the overall clinical characteristics, therapeutic status and prognosis pattern of gastric cancer liver metastasis (gclm) in china.


Eligibility criteria:
inclusion criteria: * gastric cancer liver metastases cases aged over 18 years old; * primary gastric carcinoma (including different histopathological types) confirmed by biopsy or surgery (pre-, intra- or post- treatment); * in hospital cases between 2020/01/01 to 2019/12/3. exclusion criteria: * poor compliance to treatment or lost to follow-up; * gross loss of clinical data.

Keywords: prognosis multidisciplinary treatment c-gclm classification gastric cancer liver metastasis
organ dysfunction associated with intra abdominal pressures in liver transplantation

Conditions: Liver Diseases; Intra-Abdominal Hypertension; Cirrhosis, Liver; Organ Dysfunction Syndrome

Summary: patients with end stage liver disease have varying degrees of intra-abdominal hypertension (iah) due to the presence of ascites. the perioperative events may either relieve or aggravate the intra-abdominal pressures. intra-abdominal hypertension has damaging effect on various organ systems. there is an increase in intracranial pressures and a decrease in cerebral perfusion pressures associated with iah . in the heart, there is an increase of right atrial pressures, increase in systemic vascular resistance and decrease in cardiac output . pulmonary complications include increase in the peak, mean and plateau airway pressures, with decreased compliance . renal dysfunction is an early effect of raised intra-abdominal pressure, resulting from decreased renal blood flow, shunting of blood to the medulla, mechanical compression of the kidneys and increased pressures in the renal veins . we would study the intra-abdominal pressures in liver transplant recipients and record hemodynamic, respiratory, cardiac and renal function prospectively. follow up data for 6 days for neurological, respiratory, cardiac and renal complications will be collected, along with hospital stay, icu stay and mortality. the association between intra-abdominal pressures and these outcomes will be analysed.


Eligibility criteria:
inclusion criteria: * patients undergoing liver transplantation * 18 to 65 years exclusion criteria: * pregnant patients * primary diagnosis of acute liver failure and acute on chronic liver failure

Keywords: organ dysfunction intra-abdominal pressure liver transplantation liver cirrhosis
molecular-based selection of patients with head and neck squamous cell carcinoma: biomarker analysis

Conditions: Head and Neck Squamous Cell Carcinoma; Locally Advanced Stage

Summary: this is an observational, prospective study enrolling patients who meet the inclusion criteria and provide consent for the use of biopsy samples collected as part of standard clinical practice. the analysis will focus on the following biomarkers: tp53, p16, cyclin d1, egfr, akt, pdl-1, and ercc1. these biomarkers will be examined in both observation groups.

the primary objective of this project is to evaluate the prognostic role of the biomarker p53, as numerous studies suggest its association with poor prognosis. this analysis will be particularly relevant for p16-positive (hpv-related) patients, who are currently considered a good prognosis category. the study aims to determine whether cases with overexpression of both p16 and p53 deviate from this assumption. a secondary objective is to validate a molecular signature in clinical practice, composed of multiple biomarkers, to assess whether specific combinations can predict treatment response. the biomarkers tp53, p16, cyclin d1, egfr, akt, pdl-1, and ercc1 will be analyzed on biopsy samples from patients with newly diagnosed, locally advanced squamous cell carcinoma of the head and neck. the study population consists of patients with locally advanced head and neck squamous cell carcinoma who have an available biopsy sample collected as part of standard clinical practice. the groups will be classified based on the treatment received: * group a: patients undergoing surgery followed by chemoradiotherapy. * group b: patients receiving exclusive chemoradiotherapy with cddp, cbdca, or cetuximab.

Eligibility criteria:
inclusion criteria: 1. patients aged \> 18 years 2. written informed consent approved by the competent independent ethics committee 3. histopathological diagnosis of squamous cell carcinoma of the head and neck region originating from one of the following organs or structures: oral cavity, oropharynx, larynx, hypopharynx 4. locally advanced stage: from t1n1m0 to t4n3m0 5. availability of a tissue sample from a biopsy performed according to clinical practice guidelines. exclusion criteria: 1. recurrent/metastatic disease 2. presence of a synchronous second tumor
exploratory study on predicting cidp patients' decline during iv immunoglobulin treatment adaptation feasibility.

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy

Summary: acticidp is a monocentric academic study. patients with chronic inflammatory demyelinating polyradiculoneuritis may be included on a voluntary basis. the investigators plan to include a group of approximately 40 patients with cidp. the investigators have planned to assess patient every three months for a year. after each visit, participants will wear actimyo for one month daily.

on each visit, participants will undergo a clinical examination with mrc sum score, a miss score and a i-rods score. they will perform few tests 6-minutes walk test (6mwt), a myogrip measurement, and a 9 hole peg test (9hpt) and will answer to some questionaires (miss, incat and pgic). actimyo is an innovative device intended to be used in a home-based environment. it is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.the two watches can be worn as wristwatch or placed near the ankle.

Eligibility criteria:
inclusion criteria: * diagnosed with cidp or possible cidp based on 2021 ean/pns criteria2. * treated with ivig (≤1g/kg/3-8week) * clinically stable disease for 3 months (according to treating physician opinion). * no treatment withdrawal failure within 1 year * age over 18 years exclusion criteria: * significant cognitive or communication disorders * surgery or serious traumatic injury ≤ 6 months * non ambulant patient * current participation to a therapeutic trial * anti-myeline antibodies (anti-mag) positive or nodo-paranodopathy * other autoimmune disease that requires corticosteroids, ivig, plasma exchange treatment * pregnancy or breastfeeding * any other condition that, according to the investigator, could significantly interfere with patient evaluation or safety.

Keywords: actimyo accelerometry daily living
observational study on the diagnostic evaluation of the intestinal microbiota of patients with covid-19.

Conditions: COVID-19

Summary: in the context of the covid-19 pandemic, the role of the gut microbiome is yet unknown. the aim of this trial is to evaluate the clinical contribution of the gut microbiome composition and diversity on the disease severity and to estimate the viral load in stool samples.


Eligibility criteria:
inclusion criteria: * covid-19 positive patients: hospitalised patients diagnosed with covid-19 in one of the investigating sites, and able to provide a stool sample. * control subjects: medical and paramedical personnel working at one of the investigating sites, having been in direct contact with the patients. * aged between 18 and 95 years. * subjects able to read the french-language study information leaflet. * patients with social cover. exclusion criteria: * covid-19 negative patients. * patients in critical care, heart failure or respiratory failure. * unable to provide naturally a stool sample. * patients without social cover. * pregnant women

Keywords: microbiome ; sars-cov-2 ; metagenomic ; stool
detection of colorectal cancer in peripheral blood by septin 9 dna methylation assay

Conditions: Colorectal Cancer

Summary: epigenomics is developing a colon cancer screening assay based on differential methylation of specific cpg sites for the detection of early stage disease. a genome-wide methylation analysis and oligonucleotide array study using dna from various stages of colon cancer and normal tissue have been completed to obtain candidate cpg markers. based on results obtained in the above studies, epigenomics has moved to the final stages of feasibility with a specific, highly sensitive real-time marker assay that is able to detect colon cancer dna in blood plasma.

from public health as well as health economics perspectives, the poor adoption of current screening options limits the effectiveness of crc screening initiatives; as stated by sidney winawer, md, "the best test is the one that gets done." current crc screening guidelines include fobt, sigmoidoscopy (alone or with fobt), or colonoscopy. non-invasive screening is conducted using fobt, which while inexpensive, exhibits a low compliance rate (around 16% in the us) due to its use restrictions, perceived inconvenience and lack of consumer acceptance. the gold standard procedure for crc detection is colonoscopy; it exhibits excellent performance characteristics, but has a limited utility as a first line screen due to its high cost, healthcare delivery resource limitations, and inadequate patient acceptance. it is believed a noninvasive, first-line screening assay capable of detecting individuals with colorectal disease, confirmed by colonoscopy, would have greater utility for population screening. epigenomics has identified methylated gene regions that are specific for colorectal cancer or pre-malignant tissue. aberrantly methylated genes represent attractive candidate markers for cancer screening, as cancer-specific methylation changes occur early in tumorigenesis, appear to be stable, yield a positive amplifiable signal, and can be assayed with high analytical sensitivity. since methylation occurs early and in distinct genomic areas, it is possible to achieve high clinical sensitivity with a small number of methylated dna markers. studies have shown that aberrantly methylated dna markers can be detected in tissue and body fluids and are highly correlated to colorectal cancer.

Eligibility criteria:
inclusion criteria: * group 1 diagnosis of colorectal cancer exclusion criteria: * group 2 diagnosis of colorectal cancer

Keywords: colorectal cancer screening biomarker plasma blood
effects of protein and fiber at breakfast on appetite, blood sugar, and cholesterol

Conditions: Brain Activity; Appetite; Ingestive Behavior; Glucose Control; Cholesterol

Summary: the objectives of the research are to assess the effects of increased protein and fiber intake at breakfast on neural activation in brain regions associated with appetitive drive and reward-driven eating, measures of subjective appetite, and ingestive behavior in overweight adults. additional outcomes of interest include the effects of the breakfast intervention on blood sugar and cholesterol profiles.

the objectives of the research are to assess the effects of increased protein and fiber intake at breakfast on neural activation in brain regions associated with appetitive drive and reward-driven eating, measures of subjective appetite, and ingestive behavior in overweight adults. additional outcomes of interest include the effects of the breakfast intervention on 24-hour glucose profile as well as fasting and postprandial glycemic and lipemic regulation. the investigators will test the effects of consuming breakfasts with normal protein/normal fiber (npnf), normal protein/high fiber (nphf), high protein/normal fiber (hpnf), and high protein/high fiber (hphf) for two weeks in a randomized cross-over study.

Eligibility criteria:
inclusion criteria: * male or female * age 21 - 45 years * bmi 25-29.9 kg/m2 exclusion criteria: * irregular menstrual cycles * current smoker * medications or supplements that affect appetite * pregnant or lactating * not weight stable * acutely ill * diabetic * claustrophobic * any implantation unsafe in magnetic resonance imaging (mri) environment
systemic inflammatory response evaluation with the use of inhaled anesthetic sevoflurane during cpb

Conditions: Inflammatory Response

Summary: cardiac surgery has evolved considerably after the advent of cardiopulmonary bypass (cpb), a feature that allowed more precision and tranquility to the heart surgeon. but their influence on exacerbation of inflammatory response can unbalance the whole homeostasis so happens surgical trauma. the attenuation of the systemic inflammatory response in major surgeries like cardiac surgery for aortic aneurysm appears to represent an important advance in reducing morbidity and mortality of these patients. some studies suggest that inhaled anesthetics such as sevoflurane appear to play an important role in this control, but the mechanism by which this happens is still unclear. this study has the primary purpose of analyzing from a clinical study sevoflurane inhalation anesthetic can change the inflammatory response induced by cpb, significantly reducing the release of inflammatory markers, especially elastase pmn.


Eligibility criteria:
inclusion criteria: * age over 18 years * cardiac surgery elective of coronary artery bypass graft with cardiopulmonary bypass (cpb) * the informed consent signature savvy exclusion criteria: * use of steroids or anti-inflammatory drugs routine * presence of asthma, copd, autoimmune diseases * participation in other clinical studies * presence of decompensated heart failures, liver or kidney * combined elective surgery (ex .: aneurysm correction + cabg) * acute myocardial infarction in the last 30 days * unstable angina * and obesity (bmi\> 50kg / m2)

Keywords: sevoflurane micrornas inflammatory response cytokines anesthetics, inhalation macrophage inflammatory proteins
assessing response to albuterol in bronchiolitis

Conditions: Bronchiolitis

Summary: bronchiolitis is a significant cause of morbidity and hospitalizations in children, accounting for more than 125,000 hospitalized children per year in the united states. although treatment is largely supportive, bronchodilator medications such as albuterol are frequently used due to increased pulmonary resistance in this population.2-4 however, despite four decades of clinical trials, the efficacy of albuterol in the treatment of bronchiolitis has yet to be proven. this inconsistency is due in part to the lack of sufficiently sensitive methods for the evaluation of lung function and thus the response to albuterol in infants. because of the difficulties in evaluating the response to therapy, healthcare providers are forced to rely on their physical examination skills or a clinical scoring system, both of which are highly subjective in this population. the investigators propose to conduct a prospective observational study of healthcare providers to determine the accuracy of clinical assessment as compared to that of pulmonary mechanics in a population of children intubated and mechanically ventilated for bronchiolitis.

we propose to conduct a prospective observational study of healthcare providers to determine the accuracy of clinical assessment as compared to the assessment of pulmonary mechanics in a population of children intubated and mechanically ventilated for bronchiolitis. before and at 20 minutes following a routinely scheduled albuterol treatment, measurements of pulmonary mechanics obtained as part of the child's clinical care will be compared to a healthcare provider's simultaneous clinical assessment. three healthcare providers (a nurse, physician, and respiratory therapist) will assess the child during these time periods. data regarding their observations will be recorded using a data collection tool (attached). healthcare providers will be blinded to each other's assessments and to the measurements of pulmonary mechanics. using sensitivity and specificity analysis, the healthcare provider's assessment of response will be compared to the standard assessment of response according to the measurements of pulmonary mechanics. a precision of the estimate of sensitivity and specificity will be calculated. clinical characteristics of the child will be recorded. each child may be assessed on up to three occasions if that child receives greater than 1 dose of albuterol. however, no more than 3 providers will assess the child at one time.

Eligibility criteria:
inclusion criteria: * hospitalization with a primary admission diagnosis of bronchiolitis * age between birth and 2 years * intubated with \< 1 cm h2o leak around endotracheal tube * receiving inhaled albuterol therapy exclusion criteria: - not meeting inclusion criteria

Keywords: pediatric